Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drisapersen Extension Study in DMD
NCT01480245Phase 3Terminated
- Sponsor
- GSK
- Start
- Sep 2011
- Primary completion
- Mar 2014
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 24
01
Overview
A Phase 3 trial of drisapersen in Duchenne muscular dystrophy (DMD), sponsored by GSK. Started Sep 2011; status: terminated.
02
Drugs
drisapersen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT01480245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01480245.